BTG3 and uveitis: We found that female patients had a higher probability of achieving remission at 12 months than male patients (p:0.013), with no other differences for the JIA subcategory (p:0.617), uveitis (p:0.224), or antinuclear antibody (ANA) status (p:0.704).